It's emblematic of MSB's management of their data, and one of the reasons that the Macbank guy is so critical. Putting selected and limited data out via press release is no way to facilitate sensible assessment of scientific performance. Peer-reviewed publications in worthy journals is key to getting an unvarnished view of the company's clinical data.
Yes I could ask the company - but I believe that they have a responsibility to report newsworthy issues, whether good, bad or indifferent. Roaring silences such as this - when seen in the context of not a single negative announcement since going public - make me, personally, uncomfortable.
Others, perhaps prefer to take theses announcements at face value.
Ann: P3 trial initiated, positive 24 mth P2 results in back pain, page-13
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |